Craig Gibbs, Ph.D., M.B.A. has been Chief Executive Officer and Acting Chairman of the Board of Asher Biotherapeutics Inc. since September of 2020. He is also Chairman of the Board of Inipharm Inc. Previously from September 2015 until April 2020, Dr. Gibbs was the Chief Business Officer at Forty Seven Inc. and served on the on the Board of Directors of Aridis Pharmaceuticals Inc. from 2015 to 2023, the Board of Trustees of the Leukemia and Lymphoma Society from 2020 to 2023 and on the Board of Directors of Tobira Therapeutics from May 2013 to September 2016. From 1992 to 2013 Dr. Gibbs worked for Gilead Sciences in a variety of leadership positions spanning Biology Research, Corporate Development and, most recently, Vice President of Commercial Strategy/Commercial Planning and Operations. Prior to Gilead, Dr. Gibbs served as a Scientist in the Department of Protein Engineering at Genentech, Inc. He received his B.Sc. in Biochemistry from Massey University in New Zealand, his Ph.D. in Molecular Biology from the University of Glasgow in Scotland and his M.B.A. from Golden Gate University in San Francisco.